APA (7th ed.) Citation

A, C., MK, C., Y, S., TR, C., A, B., Y, R., . . . JT, R. A. (2023). Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV - Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial. EClinicalMedicine, 60, 102025. https://doi.org/10.1016/j.eclinm.2023.102025

Chicago Style (17th ed.) Citation

A, Compagnucci, et al. "Nucleoside/nucleotide Reverse Transcriptase Inhibitor Sparing Regimen with Once Daily Integrase Inhibitor Plus Boosted Darunavir Is Non-inferior to Standard of Care in Virologically-suppressed Children and Adolescents Living with HIV - Week 48 Results of the Randomised SMILE Penta-17-ANRS 152 Clinical Trial." EClinicalMedicine 60 (2023): 102025. https://doi.org/10.1016/j.eclinm.2023.102025.

MLA (9th ed.) Citation

A, Compagnucci, et al. "Nucleoside/nucleotide Reverse Transcriptase Inhibitor Sparing Regimen with Once Daily Integrase Inhibitor Plus Boosted Darunavir Is Non-inferior to Standard of Care in Virologically-suppressed Children and Adolescents Living with HIV - Week 48 Results of the Randomised SMILE Penta-17-ANRS 152 Clinical Trial." EClinicalMedicine, vol. 60, 2023, p. 102025, https://doi.org/10.1016/j.eclinm.2023.102025.